- Home
- IGR vs DNTH Comparison
IGR vs DNTH Comparison
Compare IGR & DNTH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IGR
- DNTH
- Stock Information
- Founded
- IGR 2004
- DNTH 2015
- Country
- IGR United States
- DNTH United States
- Employees
- IGR N/A
- DNTH N/A
- Industry
- IGR Finance Companies
- DNTH Biotechnology: Pharmaceutical Preparations
- Sector
- IGR Finance
- DNTH Health Care
- Exchange
- IGR Nasdaq
- DNTH Nasdaq
- Market Cap
- IGR 821.6M
- DNTH 806.8M
- IPO Year
- IGR N/A
- DNTH N/A
- Fundamental
- Price
- IGR $6.36
- DNTH $26.62
- Analyst Decision
- IGR
- DNTH Strong Buy
- Analyst Count
- IGR 0
- DNTH 7
- Target Price
- IGR N/A
- DNTH $44.67
- AVG Volume (30 Days)
- IGR 747.7K
- DNTH 141.7K
- Earning Date
- IGR 01-01-0001
- DNTH 08-08-2024
- Dividend Yield
- IGR 13.93%
- DNTH N/A
- EPS Growth
- IGR N/A
- DNTH N/A
- EPS
- IGR N/A
- DNTH N/A
- Revenue
- IGR N/A
- DNTH $4,118,000.00
- Revenue This Year
- IGR N/A
- DNTH $41.61
- Revenue Next Year
- IGR N/A
- DNTH N/A
- P/E Ratio
- IGR N/A
- DNTH N/A
- Revenue Growth
- IGR N/A
- DNTH 8.57
- 52 Week Low
- IGR $3.88
- DNTH $0.68
- 52 Week High
- IGR $5.70
- DNTH $33.77
- Technical
- Relative Strength Index (RSI)
- IGR 70.36
- DNTH 42.69
- Support Level
- IGR $6.22
- DNTH $26.79
- Resistance Level
- IGR $6.45
- DNTH $29.06
- Average True Range (ATR)
- IGR 0.14
- DNTH 1.57
- MACD
- IGR 0.01
- DNTH -0.21
- Stochastic Oscillator
- IGR 84.43
- DNTH 6.49
About IGR CBRE Global Real Estate Income Fund of Beneficial Interest
CBRE Clarion Global Real Estate Income Fund is the United States based diversified, closed-end management investment company. Its objective is high current income and its secondary objective is capital appreciation. The fund invests a majority of its total assets in income-producing real estate securities located mainly in the developed markets of North America, Europe, Australia, and Asia. Its portfolio of investments consists of different sectors such as diversified, retail, industrial, residential, hotels, healthcare, and other sectors.
About DNTH Dianthus Therapeutics Inc.
Dianthus Therapeutics Inc is a clinical-stage biotechnology company dedicated to designing and delivering novel, monoclonal antibodies with improved selectivity and potency over existing complement therapies. The company is focused on developing next-generation complement therapeutics for patients living with severe autoimmune and inflammatory diseases. The company is comprised of an experienced team of biotech and pharma executives. The company's pipeline consists of DNTH103 a subcutaneous active C1s antibody.